Prescription Eye Drops Recalled for Manufacturing Control Deviations
Akorn, Inc. is voluntarily recalling over 2 million bottles of Tobramycin Ophthalmic Solution due to Current Good Manufacturing Practice deviations affecting four product lots distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for Current Good Manufacturing Practice deviations affecting 2.1 million bottles of an ophthalmic solution distributed nationwide. While no illnesses have been reported, ophthalmic solutions are risk-of-harm products requiring strict manufacturing controls due to the sensitivity of eye tissues.
Plain-English summary
Tobramycin Ophthalmic Solution, USP 0.3%, 5 mL per dropper bottle, manufactured by Akorn, Inc. of Lake Forest, Illinois, is being recalled. The product carries NDC (National Drug Code) 17478-290-10, and approximately 2,095,068 bottles are affected.
The recall was initiated by Akorn, Inc. due to Current Good Manufacturing Practice (CGMP) deviations. The recall applies to four specific lots: Lot 1C56A (expiration 2/28/2023), Lot 1J50A (expiration 8/31/2023), Lot 1K61A (expiration 9/30/2023), and Lot 1M27A (expiration 11/30/2023).
The product was distributed nationwide in the United States. The firm voluntarily initiated the recall on October 13, 2022, which was classified as FDA Class II by the FDA on January 13, 2023. The recall status is ongoing.
Patients and healthcare providers who have or use affected lots should consult with their prescribing provider or pharmacist regarding this recall.
The recalled product
- Product
- Tobramycin Ophthalmic Solution, USP, 0.3%, 5 mL per dropper bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC 17478-290-10
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 2,095,068
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot: 1C56A
- EXP 2/28/2023
- 1J50A
- EXP 8/31/2023
- 1K61A
- EXP 9/30/2023
- 1M27A
- EXP 11/30/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-09-09
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- HighU2 Total Knee System Femoral Valgus Adaptor Recall
FDA (Devices) · 2026-08-12
- HighUnited Orthopedic Corp. Recalls Femoral Valgus Offset Adaptors for U2 Total Knee System
FDA (Devices) · 2026-08-12
- HighKnee Prosthesis Trial Recall for Manufacturing Defect
FDA (Devices) · 2026-08-12